UK Sarah Haywood, CEO of MedCity, the life science cluster for London, Oxford and Cambridge in the southeast of England, discusses the organization’s strategy, key achievements, Brexit, and supporting SMEs. Why was there a need to create yet another life sciences cluster four years ago? Aren’t there already enough in this…
Baltics Janis Meiksans, general manager at TEVA Baltics, explains how the base of the company’s success is what they call ‘generic evangelism’ and how from being a marketing and distribution organization in the region, they successfully managed to rank number one pharmaceutical company by sales. Janis, can you talk our international…
Tunisia The long-awaited conference marking the launch of the company cluster of Sidi Thabet (a city in the governorate of Ariana, 20 minutes from Tunis airport) took place on September 28th 2017 at the Tunis export centre (CEPEX) and revolved around the theme: “Sidi Thabet BioTechpole: serving innovation in the pharmaceutical…
Austria Harald Isemann, chairman of the Vienna Biocenter (VBC) – one of the leading life science hubs in Europe – and Managing Director of the Institute of Molecular Pathology (IMP), a VBC member, provides insights into the main tasks of the VBC, the organization of the IMP and the challenges it…
Japan Kenichi Tamiya, director for Biomedical Policy at the Kobe City Government and managing director of the Kobe Foundation for Biomedical Research and Innovation (FBRI), discusses the central Japanese city of Kobe’s significant potential as a cutting-edge R&D hub for both the national and global life science industries. “Alongside promoting translational…
Hong Kong The Hon. Fanny Law Fan Chiu-fun, chairperson, and Prof. Daniel Lee, head of the Biomedical Technology Cluster, at Hong Kong Science and Technology Parks Corporation (HKSTP) discuss Hong Kong’s potential as an innovation hub, as well as the role that life sciences has to play within this. They also touch…
Taiwan Wayne Wang, director general of Hsinchu Science Park (HSP), the country’s largest and oldest innovation cluster and the first in Taiwan to establish a science park exclusively dedicated to the life sciences industry, documents the potential of HSP as a world-class eco-system for start-ups, local and international mature companies, prestigious…
Pharma With nearly €4 billion of capital investment in large molecule manufacturing underway, Ireland’s strategy to become a premier destination for biologics FDI has proven to be successful, according to BioPharmaChem Ireland director Matt Moran. Yet, Ireland today is much more than a manufacturing hub, and is well on its way to…
PPP Known as “Ireland’s university of Enterprise,” Dublin City University’s research and educational philosophy is very much informed by the institution’s strong partnerships and collaborations with the private sector. Professor Brian MacCraith discusses the institutions’ unique approach to academic-private collaborations and some of the initiatives currently underway in the life science…
Pharma Lyonbiopole was established in 2005 as a cluster designed to support the local business community focused on infectious diseases and microbiology. Philippe Archinard, the Biopole’s president, traces the evolution of the cluster over the last decade while underscoring the critical importance of transparency and collaboration between government, industry and academia.…
Pharma Mr Kimelfeld and Ms Labat run us through the exceptional history of Lyon and the region in the life sciences field, how Lyon is considered to be the birthplace of bio industries in France, and why life sciences will remain an economic driving force of the local economy. Could you…
Pharma Pharmaceuticals Giuseppe Martini, President at the National Technological Cluster: Advanced Life Sciences in Italy (ALISEI) discusses the founding of the ALISEI cluster, its main missions and how it helps Italy to promote itself as a research destination on a pan-European level. Mr. Martini, can you give our readers a brief overview…
See our Cookie Privacy Policy Here